Latest Breaking News On - New amsterdam pharma - Page 1 : comparemela.com

Daniel Gaudet, MD, PhD: Contextualizing Plozasiran Data from SHASTA-2, Upcoming MUIR Data

Daniel Gaudet, MD, PhD, discusses SHASTA-2 data and what cardiologists could learn from the forthcoming 48-week MUIR trial data from EAS 2024.

Daniel gaudetEli lillyBoehringer ingelheimAmerican college of cardiologyNovo nordiskArrowhead pharmaceuticalsAmerican collegeAnnual scientific sessionArrowhead pharmaceuticalNew amsterdam pharma

NanoPhoria appoints Dr Suman Shirodkar as Chair and Prof Michael Davidson as Non-Executive Member of the Board of Directors

NanoPhoria appoints Dr Suman Shirodkar as Chair and Prof Michael Davidson as Non-Executive Member of the Board of Directors
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Lucia faccioMichaelh davidsonSuman shirodkarCambridge epigenetixMedicines companyBristol myers squibbOmthera pharmaceuticalsUniversity of chicagoMckinsey coMichael davidsonNon executive memberLarkspur biosciencesLipid clinicSofinnova partnersChief executive officerNew amsterdam pharma

Tracking Ole Andreas Halvorsen s Viking Global Portfolio – Q3 2023 Update

Tracking Ole Andreas Halvorsen s Viking Global Portfolio – Q3 2023 Update
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Amylyx pharmaSherwin williamsJulian robertsonBiomarin pharmaAndreas halvorsenScott olsonJohn vincentLululemon athleticaBridgebio pharmaGuardant healthRoivant sciencesInternational flavorsArista networksDanaher corpAllan and co gathering in sun valleyProgressive corp

New PCSK9 Inhibitor Allows 3-Month Treatment Intervals

"It s a new antibody that has a long half-life so each treatment can be prolonged."

United statesSouth australiaEli lillyStephen nichollsVictorian heart instituteCapital medical universityAmerican heart associationMedicines companyBoehringer ingelheimMonash universityAdd on therapyPatients with non familial hypercholesterolemiaMixed hyperlipidemiaBeijing anzhen hospitalAmerican heartNew amsterdam pharma

Muvalaplin and Olpasiran Show Promise in Lowering Lp(a)

Oral muvalaplin lowered lipoprotein(a) in a phase 1 study, and injectable olpasiran did so in an extension of a phase 2 study, both with no adverse safety signals, researchers report.

United statesNoord hollandUnited kingdomSouth australiaEli lillyLouise bowmanMichellel odonoghueStephenj nichollsUniversity of oxfordEuropean society of cardiologyHarvard medical schoolMedicines companyAmerican heart association scientific sessionsMonash universityVictoria heart instituteBoehringer ingelheim